Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose titrated clinical trial with a placebo-controlled, double-blind, randomised, cross-over phase to demonstrate the efficacy of 400 microg Intranasal fentanyl (INFS) dose strength, and to evaluate 12 weeks safety and nasal tolerability of all dose strengths between 50 microg and 400 microg, in cancer patients with breakthrough pain.

Next Previous
Trial Profile

A dose titrated clinical trial with a placebo-controlled, double-blind, randomised, cross-over phase to demonstrate the efficacy of 400 microg Intranasal fentanyl (INFS) dose strength, and to evaluate 12 weeks safety and nasal tolerability of all dose strengths between 50 microg and 400 microg, in cancer patients with breakthrough pain.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms NOSE-400
  • Sponsors Takeda

Most Recent Events

  • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 21 Aug 2012 Planned End Date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
  • 02 Sep 2011 Planned end date (Jul 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top